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Nurse Exposure to Waste Anesthetic Gases in a  
Post Anesthesia Care Unit 
 
Larry A. Flack II 
 
ABSTRACT 
 
 
 
 
It has been estimated that over 200,000 healthcare 
professionals may be exposed to waste anesthetic gases and are at 
risk of occupational injury.  In 1977, the National Institute for 
Occupational Safety and Health (NIOSH) issued the publication:  
Criteria for a Recommended Standard….Occupational Exposure to 
Waste Anesthetic Gases and Vapors.  This publication was based 
primarily on scientific evidence from human and animal studies 
suggesting that chronic exposures to anesthetic gases increases the 
risk of both spontaneous abortion and congenital abnormalities in 
offspring among female workers and wives of male workers exposed to 
waste anesthetic gases.  In this recommended standard, NIOSH 
defines the recommended exposure limits (REL) for nitrous oxide and 
halogenated anesthetics.  NIOSH recommended a time-weighted 
average (TWA) REL of 25 parts per million (ppm) for nitrous oxide over 
the period of administration.  The REL for halogenated anesthetic 
gases is a ceiling limit of two ppm.   
In this study, waste anesthetic gas exposures to seven Post 
Anesthesia Care Unit (PACU) nurses were quantified during one day of 
air sampling within their breathing zones.   
Nitrous Oxide was sampled using a ChemExpressTM Personal 
Monitor (Assay Technology, Inc. Pleasanton, CA) attached to the nurse’s 
lapel for approximately three hours.  A total of 15 samples were 
collected.  Isoflurane, desflurane, and sevoflurane were sampled using a 
ChemExpressTM Personal Monitor (Assay Technology, Inc. Pleasanton, 
CA) attached to the nurse’s lapel for approximately three hours.  A total 
of 15 samples were collected.  In addition, Isoflurane, desflurane, and 
sevoflurane were also sampled using Anasorb® 747 sorbent tubes (SKC, 
Inc. Eighty Four, PA) to compare the passive and active sampling 
methods.  The tubes were attached to the nurses lapel for one hour.  A 
total of 15 samples were collected. 
 v 
The exposures to nitrous oxide and halogenated anesthetics were 
below the NIOSH RELs.   
An Analysis of Variance (ANOVA) showed a statistically significant 
difference (p < 0.05) in the active and passive sampling methodologies.  
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Introduction 
  
In 1977, the National Institute for Occupational Safety and 
Health (NIOSH) issued the publication:  Criteria for a Recommended 
Standard….Occupational Exposure to Waste Anesthetic Gases and 
Vapors.  This publication was based primarily on scientific evidence 
from human and animal studies suggesting that chronic exposures to 
anesthetic gases increases the risk of both spontaneous abortion and 
congenital abnormalities in offspring among female workers and wives 
of male workers (NIOSH, 1977).  In addition, acute exposures to 
waste anesthetic gases have been associated with headaches, nausea, 
fatigue, and irritability (NIOSH, 1977).  The scientific evidence used to 
develop the recommended standard has been questioned, particularly 
regarding the validity and reproducibility of the studies.  Nonetheless, 
NIOSH issued recommended exposure limits (REL) for nitrous oxide 
and halogenated anesthetic gases (e.g. sevoflurane, desflurane, 
isoflurane, halothane).  The REL for nitrous oxide is a time weighted 
average (TWA) concentration of 25 parts per million (ppm) over the 
period of administration (NIOSH, 1977).  The REL for halogenated 
anesthetic gases is a ceiling limit of two ppm (NIOSH, 1977).   
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 The majority of human evidence used to develop the NIOSH 
publication involved mainly hospital operating room personnel.  
However, NIOSH believes that other anesthetizing areas have the 
potential for exposure to waste anesthetic gases that could produce 
adverse health effects in workers.   
 As of 2006, the Occupational Safety and Health Administration 
(OSHA) does not have occupational exposure limits for specific waste 
anesthetic gases.  However in 1999, they issued a Waste Anesthetic 
Gas Guidance Document (OSHA Fact Sheet No. 91-38) that 
recommends exposure limits identical to the NIOSH REL’s. OSHA does 
regulate exposures to waste anesthetic gases under Section 5(a)(1) of 
the Occupational Safety and Health Act, referred to as the General 
Duty Clause. 
 An area of particular concern over the past several years is the 
Post Anesthesia Care Unit (PACU).  Nurses working in a PACU have the 
potential to be exposed to waste anesthetic gases at levels that exceed 
the RELs.  The potential for nurse exposure to these gases occurs 
when patients are disconnected from scavenged anesthesia machines 
in the operating rooms and transported to the PACU.  While in the 
PACU, the patient exhales waste anesthetic gases into the ambient air.  
Nurses caring for these patients often work within two to three feet of 
the patient’s breathing zone where waste anesthetic gas 
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concentrations could be excessive.   Nurses caring for patients 
throughout the day have the potential to be exposed to these gases at 
concentrations that exceed those recommended by NIOSH.  
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Literature Review 
 
NIOSH Recommended Exposure Limits 
 
 In 1977, NIOSH developed recommended exposure limits by 
investigating and compiling human and animal studies concerning 
exposures to nitrous oxide and various volatile anesthetics.  The 
scientific evidence derived from these studies showed that exposure to 
anesthetic gases may cause: increased risk of spontaneous abortions 
and congenital abnormalities in offspring among female workers and 
wives of male workers chronically exposed to anesthetic gases; 
increased risk of liver and kidney diseases; increased number of 
resorptions in pregnant animals; and decrements in performance, 
cognition, audiovisual ability, and dexterity (NIOSH, 1977).   
In one particular epidemiologic study, the results indicated that 
female anesthesiologists, nurse-anesthetists, operating room nurses, 
and technicians in the exposed group (exposure during the first 
trimester of pregnancy and the preceding year) had a 1.3-2 times 
increased risk of spontaneous abortion than that of the unexposed 
group (NIOSH, 1977).  An analysis of the exposed and non-exposed 
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female anesthesiologist groups showed a 60% (p<0.01) increase in 
congenital abnormalities in the children of the exposed group (NIOSH, 
1977).   Another analysis of the female anesthesiologists exposed 
group suggested a two-fold increase in congenital abnormalities in 
their children compared with the unexposed female physician 
anesthesiologists and female pediatricians (p=0.13 and 0.07, 
respectively) (NIOSH, 1977).  The same study showed a 25% increase 
(p=0.04) in the incidence of congenital abnormalities for the children 
of exposed physician anesthesiologists wives (NIOSH, 1977).  The 
study did not collect data on types of anesthetic agents or 
concentrations of exposures.   
In addition to the increased risk of abortions and congenital 
abnormalities, various epidemiological studies reported evidence of 
increased risks for liver and kidney diseases among workers exposed 
to anesthetic agents (NIOSH, 1977).  During the dental portion of the 
same study above, the incidence of liver disease among dentists 
increased 156% (p<0.01) in the exposed group compared to the 
unexposed group after excluding cases of serum hepatitis due to 
exposure to blood or blood products (NIOSH, 1977).   
A study in Czechoslovakia surveyed physicians, nurses, and 
technicians to determine occupational related health problems.  The 
authors reported an increase in parenchymal damage in the liver, in 
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kidney dysfunction, and in hematologic disorders in the respondents 
commensurate with the length of service.  The study did not use 
control groups or identify anesthetic agents and concentrations 
(NIOSH, 1977).  
In addition to human epidemiologic studies, animal studies have 
investigated the toxicities of waste anesthetic gases.  A study was 
performed to investigate the potential teratogenicity of nitrous oxide in 
female rats.  The pregnant rats were exposed to 50% nitrous oxide 
and 21-25% oxygen on day eight, 25-29% nitrogen for two, four, or 
six days, or for a single day to 70% nitrous oxide and 30% oxygen 
within five-11 days.  The animals were euthanized on day 20 after 
exposure.  The most common anomalies from exposure to 50% nitrous 
oxide were death and resorption of embryos and abnormalities of 
vertebrae and ribs.  The single 24 hour period exposures within day 
five through 11 indicated a peak incidence of malformation occurring 
after exposure on day nine (NIOSH, 1977).   
Another study found that short periods of anesthesia with 
halothane were teratogenic in pregnant mice.  The mice were 
anesthetized with one or 1.5% halothane for three hours on day 12, 
13, 14, or 15 of gestation or, alternatively, on three consecutive days 
in the same period.  Upon examining the fetuses, an increase in cleft 
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palate, limb hematomas, and ossification defects in the limbs of the 
exposed animals were observed (NIOSH, 1977).    
A study to measure perceptual, cognitive, and motor skills was 
performed on 40 male volunteers between the ages of 20 and 30.  
These volunteers were exposed on two occasions to four hours of 
inhalation of either air (control) or 500 ppm nitrous oxide in air with or 
without 15 ppm halothane.  The responses to exposure of nitrous 
oxide with halothane showed statistically significant decreases in the 
performance of tasks in which attention was divided  between auditory 
and visual signals, a visual tachistoscopic test, and memory tests 
involving digit span (short term memory test using numbers) and 
recall word pairs (NIOSH, 1977).   
Another study with 100 male volunteers was performed to 
measure perceptual, cognitive, and motor skills. The following tests 
were conducted in the study:  visual perception, immediate memory, 
and a combination of perception, cognition, and motor responses 
required in a task of divided attention to simultaneous visual and 
auditory stimuli.  The tests were conducted two hours after exposure 
to the anesthetic gas and continued throughout the testing period.  
Volunteers exposed solely to nitrous oxide scored significantly lower on 
the digit-span test only.  Volunteers exposed to 50 ppm nitrous oxide 
and one ppm halothane resulted in decrements of performance for four 
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of the seven tests administered.  Volunteers exposed to 25 ppm 
nitrous oxide with 0.5 ppm halothane did not show similar effects.  
Volunteers exposed to 500 ppm of nitrous oxide alone resulted in 
decrements of performance in six of the seven tests administered 
(NIOSH, 1977).   
After reviewing the available evidence in the studies, NIOSH 
determined that the primary concern for developing an REL for 
halogentated anesthetic agents was the adverse effects on 
reproduction (NIOSH, 1977).  However, NIOSH was not able to identify 
a safe level of exposure to workers based on the studies.  Therefore, 
NIOSH recommended that exposures to halogenated anesthetic agents 
be no greater than the lowest level detected by sampling and analysis 
techniques recommended by NIOSH in 1977.  This resulted in a ceiling 
REL of two ppm for each halogenated anesthetic agent.   
 Regarding nitrous oxide, NIOSH considered the agent when 
combined with volatile anesthetics and when solely used as an 
anesthetic agent.  NIOSH determined that the primary concern for 
developing an REL for exposure to nitrous oxide alone was decrements 
in performance, cognition, audiovisual ability, and dexterity (NIOSH, 
1977).  Based on the data presented in the studies, NIOSH 
recommends an REL of 25 ppm TWA for nitrous oxide when used as 
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the sole agent for anesthesia (over the period of administration) 
(NIOSH, 1977).   
NIOSH recommends that the RELs be applied to all workers 
exposed to inhalation anesthetic agents that escape into locations 
associated with administration of, or recovery from, anesthesia 
(NIOSH, 1977). 
 Although NIOSH issued the RELs, they maintain a safe level of 
exposure cannot be defined since information on adverse health 
effects is not completely definitive and many unknown factors still 
exist (NIOSH, 1977).  NIOSH insists that the RELs should be 
considered as the upper boundry of exposure, and every effort should 
be made to keep exposures to the lowest level possible by current 
technology (NIOSH, 1977).   
 
Controversy Surrounding the Development of NIOSH RELs 
 
 Controversy surrounded the NIOSH RELs because many of the 
studies were questioned in regard to validity and reproducibility 
(Badgwell, 1996).  The main concerns centered on how to account for 
the many positive outcomes that found a statistically significant 
association between occupational exposure to waste anesthetic gases 
and adverse health consequences (Badgwell, 1996).  In addition to the 
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possibility that a direct causal relationship existed, other explanations 
included the confounding effects of low response rates, variations in 
exposure, reporting errors, and recall bias (Badgwell, 1996).   
 The American Dental Association highlights the fact that the 
investigator who performed the study upon which the NIOSH REL was 
based, stated in letters to the editor of Anesthesia Analgesia (1983) 
and Anesthesiology (1991), that he believed the conclusions of his 
study were no longer valid.  In those letters, the investigator, Dr. 
Bruce states “there is no longer any need to refer to our conclusions as 
controversial.  They were wrong, derived from data subject to 
inadvertent sampling bias and not applicable to the general 
population” (Anesthesiology, 1991).  Dr. Bruce goes on to state the 
NIOSH RELs should be revised.   
 In the 1990’s, new research was performed with new 
methodologies to correct the shortcomings of earlier work (Badgwell, 
1996).  In 1990, an epidemiological study was performed to compare 
reproductive outcomes for hospital personnel exposed to waste 
anesthetic gases in operating and recovery rooms with outcomes of 
non-exposed personnel (Badgwell, 1996).  The results of the study 
showed that women exposed to the operating room environment for 
more than two hours a week had a 124% higher rate of spontaneous 
abortion (15.6% versus 12.6%) (Badgwell, 1996).  When the data was 
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analyzed to remove confounding factors by advanced statistical 
techniques (e.g. linear logistic regression), the study showed an even 
greater increased risk, 198% for spontaneous abortion (95% 
confidence interval (CI), 1.53-2.56) and 224% for congenital 
anomalies in offspring (95% CI, 1.69-2.97)(Badgwell, 1996).   
 In 1995, a study by Rowland et al was published concerning 
occupational exposure to nitrous oxide and spontaneous abortion in 
female dental assistants (Badgwell, 1996).   The study indicated that 
women working in unscavenged environments with nitrous oxide for 
three hours or more a week had a 260% higher risk of spontaneous 
abortion (95% CI, 1.3-5.0, adjusted for age, smoking, and the number 
of mercury amalgams made each week) (Badgwell, 1996).   
 After publication of the newer studies highlighting the risks of 
exposure to waste anesthetic gases, NIOSH issued an alert bulletin in 
June 1994 for employers to control exposures to nitrous oxide during 
anesthetic administration (NIOSH Publication No. 94-118). 
 
PACU Nurses Breathing Zone during Patient Care 
 
 An observational study was conducted to determine the average 
distance between the breathing zone of nurses relative to the 
breathing zone of their patients, while in the PACU.  This study 
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involved nurses caring for 50 postoperative patients.  The distance 
from the nurse’s mouth to the mouth of the patient was recorded 
during:  admission procedures, drug administration, verbal 
communication, and airway management (Allen, et al, 1996).  The 
study showed that nurses performed their duties within four to 36 
inches from the patient’s mouth, with a majority of work performed 
within 18 to 24 inches (Allen, et al, 1996).  The average and median 
distances were less than 21 and 20 inches, respectively (Allen, et al, 
1996).  The conclusion of the investigator was that PACU nurses 
perform normal work duties an average of 21 inches from the patient’s 
mouth (Allen, et al, 1996).   
 
Anesthetic Agents 
 
 The most commonly used inhalation anesthetic agents today 
include:  nitrous oxide and the halogenated anesthetic gases (i.e. 
isoflurane, sevoflurane, and desflurane) (Wenker, 1999).   
 
Nitrous Oxide 
 
 N2O is a colorless, non-explosive, nonflammable gas at room 
temperature with a slightly sweet odor and taste (American 
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Conference of Governmental Industrial Hygienist (ACGIH), 2001).  The 
molecular weight of N2O is 44.02, approximately 1.5 times the 
molecular weight of air.  N2O was first introduced as an anesthetic 
agent in 1844 (ACGIH, 2001).  During general anesthesia, nitrous 
oxide may be administered in concentrations up to 70% (700,000 
ppm) over a time period of a few minutes to several hours (Allen et al, 
1996).  At the end of a surgery, patients exhale the anesthetic gases 
through the respiratory tract (Allen, et al, 1996).  During the 
elimination process, the alveolar concentration of the anesthetic agent 
mirrors the delivery concentration of the anesthetic agent (Allen, et al, 
1996).  As the elimination process continues, the concentration of 
exhaled anesthetic gases decreases exponentially (Allen, et al, 1996).   
 A study was performed that measured the concentration of 
nitrous oxide during the elimination process.  This study showed that 
after inhalation of 50% nitrous oxide for five minutes, more than two 
hours were required for the end-tidal concentrations of nitrous oxide to 
decrease to the NIOSH REL of 25 ppm.  Inhalation of 50% nitrous 
oxide for 30 minutes required four hours before the end-tidal 
concentrations decreased to the NIOSH REL.   The study also showed 
that patients who inhaled 50% nitrous oxide for 60 to 150 minutes, 
maintained end-tidal concentrations that exceeded 100 ppm for more 
than three hours (Allen, et al, 1996). 
 14 
Halogenated Anesthetic Gases (Isoflurane, Sevoflurane, and 
Desflurane) 
 
Isoflurane (Forane®; C3H2ClF5O) is a colorless, nonflammable 
liquid with a slight pungent odor (Baxter, 2005). The molecular weight 
of C3H2ClF5O is 184.50, approximately 6.4 times the molecular weight 
of air.  Isoflurane was involved in investigational studies in the 1970s 
(NIOSH, 1977).  The Food and Drug Administration (FDA) approved 
the anesthetic agent in December of 1980 (OSHA, 2000).  A study was 
performed to illustrate the rate of nitrous oxide and isoflurane gas 
elimination in patients undergoing elective pelvic, orthopedic, or 
abdominal surgeries (Allen, et al, 1996).  Upon patient arrival at the 
PACU, end-tidal concentrations of nitrous oxide averaged 43,708 ± 
13,190 ppm, isoflurane concentrations averaged 1,638 ± 518 ppm, 
and after 60 minutes end-tidal concentrations were 14,077 ± 9,213 
ppm for nitrous oxide and 833 ± 98 ppm for isoflurane (Allen, et al, 
1996).   
Sevoflurane (Ultane®; C4H3F7O) is a colorless, nonflammable 
liquid with a non-pungent odor (Abbott Laboratories, 2003).  The 
molecular weight of C4H3F7O is 200.05, approximately 7 times the 
molecular weight of air.  The FDA approved sevoflurane for use in the 
United States in January 1995 (Young, et al, 2005).  Desflurane 
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(Suprane®; C3H2F6O) is a colorless, nonflammable liquid with a slight 
pungent odor (Baxter, 2005). The molecular weight of C4H3F7O is 
168.04, approximately 6 times the molecular weight of air. Desflurane 
was introduced for use in the United States in 1992 (OSHA, 2000). 
Both sevoflurane and desflurane replaced isoflurane in the 1990s 
(Eger, 2005).  These three anesthetic agents are halogenated with 
fluorine, making them nonflammable and decreasing their toxicity 
(compared with chloroform based anesthetics that are no longer used) 
(Eger, 2005).  Since these anesthetic agents are relatively new, their 
toxicity has not been well characterized regarding chronic occupational 
exposure (Badgwell, 1996).   
A chemical and physical description of the anesthetic agents is 
provided in Table 1. 
 
Table 1.  Chemical and Physical Descriptions of Anesthetic 
Agents  (Merck, 2001). 
 
Anesthetic 
Agent 
CAS Number
Physical   
State
Molecular 
Weight
Density
Boiling 
Point (°C)
Nitrous Oxide 10024-97-2 Gas 44.01 1.53 (gas) -88.46
Isoflurane 26675-46-7 Liquid 184.49 1.45 48.5
Sevoflurane 28523-86-6 Liquid 200.05 1.50 58.6
Desflurane 57041-67-5 Liquid 168.04 1.44 23.5  
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Studies of PACU Nurse Exposure to Waste Anesthetic Gases  
 
 Over the past several years, there have been studies 
documenting compliance and non-compliance to the NIOSH RELs 
concerning nurse exposure to waste anesthetic gases in PACUs.  In 
one particular study performed by Sessler, et al (1996), the breathing 
zone of PACU nurses was measured for concentrations of isoflurane, 
desflurane, and nitrous oxide for each individual patient (i.e. one set of 
exposure measurements per nurse for each patient that nurse 
attended).  The results of this study were that breathing zone 
concentrations for isoflurane and desflurane exceeded NIOSH RELs in 
37% and 87% of the patients, respectively, and breathing zone 
concentrations for nitrous oxide exceeded RELs in 53% of patients.  
The investigators also mentioned in this study that the PACU averaged 
eight air changes per hour, and the majority of this air was re-
circulated.   
In another study performed by Krenzichek, et al (2002), the 
breathing zone of PACU nurses was measured for concentrations of 
waste anesthetic gases.  The results of the study indicated nurse 
exposure to nitrous oxide ranged from 2.9 ppm to 8.2 ppm (time-
weighted average over the workshift), and exposure to halogenated 
anesthetic gases were below detection limits.  The investigators 
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indicated the PACU was designed for six air changes per hour.  These 
results were below the NIOSH RELs.   
 A study performed by Bueck, et al (2001), measured exposures 
of nitrous oxide, isoflurane, desflurane, and sevoflurane to intensive 
care unit (ICU) and PACU nurses.  The results of this study indicated 
PACU nurses were exposed to desflurane and sevoflurane 
concentrations that exceeded the NIOSH RELs.  The concentrations 
were 2.80 ± 0.84 ppm for desflurane and 3.20 ± 0.62 ppm for 
sevoflurane.  PACU nurse exposure to isoflurane and nitrous oxide was 
within the NIOSH RELs.  The concentrations were 1.30 ± 0.54 ppm for 
isoflurane and 10.30 ± 2.82 ppm for nitrous oxide.  The investigators 
indicated the PACU ventilation system was designed for 15 air changes 
per hour, and 60% of the air was recirculated. 
 
Controlling Waste Anesthetic Gas Concentrations in a PACU 
 
 In a PACU, the source of waste anesthetic gases is the patient.  
An engineering control used to reduce the concentration of waste 
anesthetic gases in the ambient air of a PACU is ventilation.  In the 
NIOSH Criteria for a Recommended Standard to Occupational 
Exposures to Waste Anesthetic Gases and Vapors, it states that PACUs 
must be provided with air exchange rates in compliance with those 
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specified by the United States Department of Health, Education, and 
Welfare in Minimum Requirements of Construction and Equipment for 
Hospital and Medical Facilities (HEW Publication No. 74-4000, 
Rockville, Maryland, 1974).  NIOSH recommends ventilation systems 
be maintained regularly and verified by at least quarterly airflow 
measurements (NIOSH, 1977).  More Recently, The American Institute 
of Architects and the National Institute of Health have recommended 
dilution ventilation.  The dilution ventilation system should provide a 
minimum of six air changes per hour containing a minimum of 33% 
outside make-up air (OSHA, 2000).  The Florida Building Code also 
recommends a minimum of 6 air changes per hour containing a 
minimum of 33% outside make-up air (International Code Council, 
Inc., 2004).  The exhaust air from the ventilation system should not be 
re-circulated to other areas of the hospital. 
 OSHA recommends two work practices to help define and reduce 
exposures to waste anesthetic gases in the PACU, they include:  
periodic personnel exposure monitoring and a routine ventilation 
system maintenance program.  Personnel exposure monitoring should 
include sampling for waste anesthetic gases in the breathing zone of 
PACU nurses during peak gas levels.  The sampling event should be 
performed every six months (OSHA, 2000).    
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Purpose and Hypotheses of this Study 
 
 The purpose of this thesis was to determine the occupational 
exposure of PACU nurses to nitrous oxide and halogenated anesthetic 
gases (isoflurane, desflurane, and sevoflurane) in the PACU of a local 
Tampa hospital.   
 The hypotheses were:   
1. The levels of nitrous oxide exposure are acceptable. 
2. The levels of isoflurane exposure are acceptable. 
3. The levels of desflurane exposure are acceptable. 
4. The levels of sevoflurane exposure are acceptable. 
5. There is no difference in the results between active and 
passive sampling for the halogenated anesthetic gases. 
For the purpose of this study, “acceptable” exposures indicates 
concentrations of anesthetic agents below the NIOSH RELs. 
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Methods 
 
Participants 
 
 Participants for this study were PACU nurses.  The manager of the 
PACU selected the nurses to participate in the study.  The participants 
included six female nurses and one male nurse.  Nurses were instructed 
to perform their normal work duties during the sampling event.  Each 
nurse participating in the study signed an informed consent document 
that was approved by the University of South Florida Institutional 
Review Board.    
 
Sampling Protocol 
 
 The anesthetic gases sampled for in this study were determined 
after meeting with the Chief of Anesthesiology to determine the most 
commonly used anesthesia agents in this particular PACU.  These 
agents consisted of nitrous oxide, isoflurane, sevoflurane, and 
desflurane.  
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 Nitrous Oxide was sampled using a ChemExpressTM Personal 
Monitor (Assay Technology, Inc. Pleasanton, CA) attached to the nurse’s 
lapel for approximately three hours.  A total of 15 samples were 
collected.  The monitors were analyzed by Assay Technology, Inc. at 
their American Industrial Hygiene Association (AIHA) accredited 
laboratory in Pleasanton, CA.  The monitors were prepared for analysis 
by desorping the sorbent material (molecular sieve pellets) in a vial 
containing deionized water.  The headspace was analyzed using a gas 
chromatograph/ electron capture detector.  One field blank was sent for 
analysis.   
 Isoflurane, desflurane, and sevoflurane were sampled using a 
ChemExpressTM Personal Monitor (Assay Technology, Inc. Pleasanton, 
CA) attached to the nurse’s lapel for approximately three hours.  A total 
of 15 samples were collected.  The monitors were analyzed by Assay 
Technology, Inc. at their AIHA accredited laboratory in Pleasanton, CA.  
The monitors were prepared for analysis by desorbing the sorbent 
material (coconut charcoal) in carbon disulfide, and analyzed using a 
gas chromatograph / flame ionization detector.  One field blank was 
sent for analysis. 
 Isoflurane, desflurane, and sevoflurane were also sampled using 
Anasorb® 747 sorbent tubes (SKC, Inc. Eighty Four, PA).  OSHA 
recommends sampling for desflurane and sevoflurane using Anasorb® 
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747 sorbent tubes using a flow rate of 0.05 liters per minute (lpm) with 
a maximum air volume of 3 liters.  OSHA recommends sampling for 
isoflurane using Anasorb® 747 sorbent tubes using a flow rate of 0.05 
liters per minute (lpm) with a maximum air volume of 12 liters.  Prior to 
sampling, Buck Basic-5TM personal air sampling pumps (AP Buck, Inc. 
Orlando, FL) and low-flow tube holders (AP Buck, Inc. Orlando, FL) were 
calibrated using the Mini-BuckTM Model M-5 calibrator (AP Buck, Inc. 
Orlando, FL).  The air sampling pumps and low-flow tube holders were 
calibrated to a flow rate of 0.05 lpm.  During sampling, the personal 
sampling pump was attached to the nurse’s waist band.  The low-flow 
tube holders (containing the Anasorb® 747 sorbent tubes) were 
attached to the nurse’s lapel and were connected to the pump by ¼ 
inch Tygon tubing.  The sampling time for each sorbent tube was 
approximately one hour.  A total of 15 samples were collected.  The 
sorbent tubes were analyzed by Assay Technology, Inc. at their AIHA 
accredited laboratory in Pleasanton, CA.  The monitors were prepared 
for analysis by desorping the coconut charcoal in carbon disulfide, and 
analyzed using a gas chromatograph / flame ionization detector.  One 
field blank was sent for analysis. 
 At the conclusion of sampling, the air sampling pumps and low-
flow tube holders were calibrated to ensure proper air flow rates.  The 
pre-sampling and post-sampling flow rates were within ±5%. 
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Results 
 
 Table 2-A below lists the nitrous oxide exposure levels to nurses.  
The mass values list the amount of nitrous oxide found in the 
headspace of the sample during laboratory analysis.  All of the mass 
values have been corrected for the blank sample listed at the bottom of 
the table.   
 
Table 2-A. PACU Nurse Exposure Levels to Nitrous Oxide. 
Nurse
Sample 
ID
Mass N2O 
(µg)
Detection 
Limit (µg)
Sample 
Volume 
(L)
Sample 
Time 
(min)
Concentration1 
(ppm)
Adjusted 
Concentration2 
(ppm)
AFB0245 1.22 0.2 0.135 180 2.7 -
AFB0402 0.855 0.2 0.134 179 1.2 -
AFB1532 0.72 0.2 0.135 180 0.7 -
BFB1875 0.417 0.2 0.131 175 ND 0.6
BFB1183 0.866 0.2 0.137 183 1.3 -
CFB0485 ND 0.2 0.136 181 ND 0.6
CFB0829 0.474 0.2 0.139 185 ND 0.6
DFB1175 1.71 0.2 0.136 181 4.7 -
DFB2159 1.43 0.2 0.139 185 3.5 -
DFB1506 0.859 0.2 0.117 156 1.4 -
EFB1731 0.959 0.2 0.138 184 1.6 -
EFB1674 0.808 0.2 0.136 181 1.0 -
EFB0430 1.1 0.2 0.127 169 2.4 -
F FFB1744 0.769 0.2 0.142 189 0.8 -
G GFB0366 2.61 0.2 0.131 174 8.7 -
BLANK 0.554 0.2 - - - -
n = 15
1 Values corrected for blank sample
2 Adjusted concentration using formula (L/v2), where L is the detection limit.
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
E
A
B
C
D
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 Table 2-B lists the descriptive statistics and measures of 
variation including the upper and lower 95% confidence intervals for 
nurse exposures to nitrous oxide.   
 
Table 2-B.  Summary of Nurse Exposures to Nitrous Oxide. 
Statistics N2O (ppm)
Maximum 8.7
Minimum 0.6
Range 8.1
Mean 2.12
Median 1.3
Standard Deviation 2.18
Lower Confidence Limit (95%) 0.91
Upper Confidence Limit (95%) 3.33
n = 15
ppm - Parts Per Million  
 
Table 3-A lists the isoflurane exposure levels to nurses measured by 
passive sampling.  Table 3-B lists the isolfurane exposure levels to 
nurses measured by active sampling.   
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Table 3-A. PACU Nurse Exposure Levels to Isoflurane (Passive 
Sampling). 
Nurse Sample ID
Mass 
C3H2ClF50 
(µg)
Detection 
Limit (µg)
Sample 
Volume (L)
Sample Time 
(min)
Concentration 
(ppm)
Adjusted 
Concentration1 
(ppm)
AFD0629 ND 2 0.677 179 ND 0.39
AFD1532 ND 2 0.68 180 ND 0.39
AFD0081 ND 2 0.684 181 ND 0.39
BFD1173 ND 2 0.692 183 ND 0.38
BFD0665 ND 2 0.692 183 ND 0.38
CFD0935 ND 2 0.684 181 ND 0.39
CFD1425 ND 2 0.688 182 ND 0.39
DFD0608 ND 2 0.68 180 ND 0.39
DFD1653 ND 2 0.711 188 ND 0.37
DFD1244 ND 2 0.59 156 ND 0.45
EFD1295 ND 2 0.696 184 ND 0.38
EFD1559 ND 2 0.68 180 ND 0.39
EFD0852 ND 2 0.631 167 ND 0.42
F FFD0279 ND 2 0.699 185 ND 0.38
G GFD1606 ND 2 0.662 175 ND 0.40
BLANK ND 2 - - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
1 Adjusted concentration using formula (L/v2), where L is the detection limit.
E
A
B
C
D
 
 
Table 3-B. PACU Nurse Exposure Levels to Isoflurane (Active 
Sampling). 
Nurse
Sample 
ID
Mass C3H2ClF5 
(Front/Back)(µg)
Detection 
Limit (µg)
Sample 
Volume 
(L)
Sample 
Time 
(min)
Concentration 
(ppm)
Adjusted 
Concentration1 
(ppm)
2963A ND/ND 2 3.04 62 ND 0.09
2957A ND/ND 2 3.09 63 ND 0.09
2960A ND/ND 2 2.84 58 ND 0.09
2954B ND/ND 2 2.94 60 ND 0.09
2959B ND/ND 2 2.99 61 ND 0.09
2421C ND/ND 2 3.00 60 ND 0.09
2423C ND/ND 2 2.95 59 ND 0.09
2419D ND/ND 2 3.05 61 ND 0.09
2962D ND/ND 2 3.25 65 ND 0.08
2414D ND/ND 2 3.00 60 ND 0.09
2417E ND/ND 2 3.04 62 ND 0.09
2415E ND/ND 2 2.99 61 ND 0.09
2418E ND/ND 2 2.94 60 ND 0.09
F 2955F ND/ND 2 2.94 60 ND 0.09
G 2958G ND/ND 2 2.84 58 ND 0.09
BLANK ND/ND 2 - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
E
1 Adjusted concentration using formula (L/v 2), where L is the detection limit.
A
B
C
D
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Table 4-A lists the sevoflurane exposure levels to nurses 
measured by passive sampling.  Table 4-B lists the sevoflurane 
exposure levels to nurses measured by active sampling.   Table 4-C 
lists the descriptive statistics and measures of variation including the 
upper and lower 95% confidence intervals for nurse exposures to 
sevoflurane. 
 
Table 4-A. PACU Nurse Exposure Levels to Sevoflurane (Passive 
Sampling). 
Nurse Sample ID
Mass 
C4H3F7O 
(µg)
Detection 
Limit (µg)
Sample 
Volume (L)
Sample Time 
(min)
Concentration 
(ppm)
Adjusted 
Concentration1 
(ppm)
AFD0629 ND 2 0.628 179 ND 0.39
AFD1532 ND 2 0.632 180 ND 0.39
AFD0081 ND 2 0.635 181 ND 0.38
BFD1173 ND 2 0.642 183 ND 0.38
BFD0665 ND 2 0.642 183 ND 0.38
CFD0935 ND 2 0.635 181 ND 0.38
CFD1425 ND 2 0.639 182 ND 0.38
DFD0608 ND 2 0.632 180 ND 0.39
DFD1653 ND 2 0.66 188 ND 0.37
DFD1244 ND 2 0.548 156 ND 0.45
EFD1295 ND 2 0.646 184 ND 0.38
EFD1559 ND 2 0.632 180 ND 0.39
EFD0852 ND 2 0.586 167 ND 0.42
F FFD0279 ND 2 0.649 185 ND 0.38
G GFD1606 ND 2 0.614 175 ND 0.40
BLANK ND 2 - - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
1 Adjusted concentration using formula (L/v2), where L is the detection limit.
C
D
E
A
B
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Table 4-B. PACU Nurse Exposure Levels to Sevoflurane (Active 
Sampling). 
Nurse
Sample 
ID
Mass C4H3F7O 
(Front/Back)(µg)
Detection 
Limit (µg)
Sample 
Volume 
(L)
Sample 
Time 
(min)
Exposure 
(ppm)
Adjusted 
Concentration1 
(ppm)
2963A ND/ND 2 3.04 62 ND 0.08
2957A 8.44/ND 2 3.09 63 0.33 -
2960A 22.2/ND 2 2.84 58 0.94 -
2959B ND/ND 2 2.99 61 ND 0.08
2954B 9.48/ND 2 2.94 60 0.39 -
2421C 5.15/ND 2 3.00 60 0.21 -
2423C 24.1/ND 2 2.95 59 0.98 -
2419D ND/ND 2 3.05 61 ND 0.08
2962D 11.4/ND 2 3.25 65 0.042 -
2414D 9.28/ND 2 3.00 60 0.37 -
2417E 4.49/ND 2 3.04 62 0.18 -
2415E 8.81/ND 2 2.99 61 0.35 -
2418E 7.57/ND 2 2.94 60 0.31 -
F 2955F ND/ND 2 2.94 60 ND 0.08
G 2958G 8.95/ND 2 2.84 58 0.38 -
BLANK ND/ND 2 - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
1 Adjusted concentration using formula (L/v2), where L is the detection limit.
C
D
A
B
E
 
 
Table 4-C. Summary of Nurse Exposures to Sevoflurane (Active 
Sampling). 
Statistics C4H3F7O (ppm)
Maximum 0.98
Minimum 0.04
Range 0.94
Mean 0.32
Median 0.31
Standard Deviation 0.29
Lower Confidence Limit (95%) 0.16
Upper Confidence Limit (95%) 0.48
n = 15
ppm - Parts Per Million  
 
Table 5-A lists the desflurane exposure levels to nurses measured 
by passive sampling.  Table 5-B lists the desflurane exposure levels to 
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nurses measured by active sampling.   Table 5-C lists the descriptive 
statistics and measures of variation including the upper and lower 95% 
confidence intervals for nurse exposures to desflurane. 
 
Table 5-A. PACU Nurse Exposure Levels to Desflurane (Passive 
Sampling). 
Nurse Sample ID
Mass 
C3H2OF6 
(µg)
Detection 
Limit (µg)
Sample 
Volume (L)
Sample Time 
(min)
Concentration 
(ppm)
Adjusted 
Concentration1 
(ppm)
AFD0629 ND 2 0.716 179 ND 0.41
AFD1532 ND 2 0.72 180 ND 0.40
AFD0081 ND 2 0.724 181 ND 0.40
BFD1173 ND 2 0.732 183 ND 0.40
BFD0665 ND 2 0.732 183 ND 0.40
CFD0935 ND 2 0.724 181 ND 0.40
CFD1425 ND 2 0.728 182 ND 0.40
DFD0608 ND 2 0.72 180 ND 0.40
DFD1653 ND 2 0.752 188 ND 0.39
DFD1244 ND 2 0.624 156 ND 0.47
EFD1295 ND 2 0.736 184 ND 0.40
EFD1559 ND 2 0.72 180 ND 0.40
EFD0852 ND 2 0.668 167 ND 0.44
F FFD0279 ND 2 0.74 185 ND 0.39
G GFD1606 ND 2 0.7 175 ND 0.42
BLANK ND 2 - - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
1 Adjusted concentration using formula (L/v2), where L is the detection limit.
D
E
A
B
C
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Table 5-B. PACU Nurse Exposure Levels to Desflurane (Active 
Sampling). 
Nurse
Sample 
ID
Mass C3H2OF6 
(Front/Back)(µg)
Detection 
Limit (µg)
Sample 
Volume 
(L)
Sample 
Time 
(min)
Exposure 
(ppm)
Adjusted 
Concentration1 
(ppm)
2963A ND/ND 3 3.04 62 ND 0.14
2957A 9.68/ND 3 3.09 63 0.45 -
2960A ND/ND 3 2.84 58 ND 0.15
2959B ND/ND 3 2.99 61 ND 0.15
2954B ND/ND 3 2.94 60 ND 0.15
2421C 4.76/ND 3 3.00 60 0.23 -
2423C 10.7/ND 3 2.95 59 0.52 -
2419D 12.2/ND 3 3.05 61 0.57 -
2962D 13.0/ND 3 3.25 65 0.057 -
2414D 6.01/ND 3 3.00 60 0.29 -
2417E ND/ND 3 3.04 62 ND 0.14
2415E 12.8/ND 3 2.99 61 0.61 -
2418E 9.46/ND 3 2.94 60 0.46 -
F 2955F 16.5/ND 3 2.94 60 0.8 -
G 2958G 8.02/ND 3 2.84 58 0.41 -
BLANK ND/ND 3 - - - -
n = 15
µg - Microgram; L - Liter; min - Minute; and ppm - Parts Per Million.
A
B
C
D
E
1 Adjusted concentration using formula (L/v 2), where L is the detection limit.  
 
Table 5-C. Summary of Nurse Exposures to Desflurane (Active 
Sampling). 
Statistics C3H2F6O (ppm)
Maximum 0.80
Minimum 0.06
Range 0.74
Mean 0.34
Median 0.29
Standard Deviation 0.22
Lower Confidence Limit (95%) 0.18
Upper Confidence Limit (95%) 0.50
n = 15
ppm - Parts Per Million  
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 Table 6 lists the exposures for nitrous oxide, desflurane, and 
sevoflurane to nurses.  The halogenated exposure column represents 
the combined effect of the halogenated exposures using the ACGIH® 
Additive Mixture Formula.   
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Table 6. PACU Nurse Exposure Levels to Nitrous Oxide used in Combination with a 
Halogenated Anesthetic.   
 
Nurse Sample ID 
(Nitrous Oxide)
Sample Time 
(Nitrous Oxide)
Nitrous Oxide 
Exposure1 
(ppm)
Sample ID 
(Halogenated)
Sample Time 
(Halogenated)
Desflurane 
Exposure 
(ppm)
Sevoflurane 
Exposure 
(ppm)
Halogenated2 
Exposure
AFB0245 180 2.7 2963A 62 ND ND -
AFB0402 179 1.2 2957A 63 0.45 0.33 0.4
AFB1532 180 0.7 2960A 58 ND 0.94 -
BFB1875 175 ND 2954B 61 ND ND -
BFB1183 183 1.3 2959B 60 ND 0.39 -
CFB0485 181 ND 2421C 60 0.23 0.21 0.2
CFB0829 185 ND 2423C 59 0.52 0.98 0.8
DFB1175 181 4.7 2419D 61 0.57 ND -
DFB2159 185 3.5 2962D 65 0.057 0.042 0.05
DFB1506 156 1.4 2414D 60 0.29 0.37 0.3
EFB1731 184 1.6 2417E 62 ND 0.18 -
EFB1674 181 1.0 2415E 61 0.61 0.35 0.5
EFB0430 169 2.4 2418E 60 0.46 0.31 0.4
F FFB1744 189 0.8 2955F 60 0.8 ND -
G GFB0366 174 8.7 2958G 58 0.41 0.38 0.4
n = 15
1 Values corrected for blank sample
2 Combined effect of Exposures (C1/T1) + (C2/T2) = 1, then the threshold of the mixture is not exceeded.
E
A
B
C
D
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In this study, a comparison of the passive and active sampling 
methods was performed.  A single factor ANOVA was used to compare 
the methods and the results are presented in Table 7.   
 
Table 7. Comparison of Active and Passive Sampling Methods for 
Halogenated Anesthetic Gases. 
Anova: Single Factor alpha = 0.05
SUMMARY
Groups Count Sum Average Variance
Passive 45 17.850 0.397 0.00041
Active 45 11.260 0.250 0.056
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 0.483 1 0.483 17.234 0.000076 3.949
Within Groups 2.464 88 0.028
Total 2.947 89  
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Discussion 
 
Nurse Exposures to Waste Anesthetic Gases 
 
 The levels of nurse exposure to nitrous oxide were below the 
NIOSH REL of 25 ppm.  The mean exposure was 2.12 ± 0.29 ppm.  The 
maximum and minimum exposures were 8.7 and 0.6 ppm.  In order to 
produce accurate descriptive statistics, censored data were adjusted by 
following formula:           
2
L
                        Equation 1 
for each nondetectable value, where L is equal to the detection limit 
(Hornung et. al, 1990).  This formula was chosen because it gives a 
better estimate of the mean and standard deviation when the data are 
not highly skewed (Hornung et. al, 1990).  The 95% confidence interval 
(CI) of the adjusted data was from 0.91 to 3.33 ppm, well below the 
NIOSH REL.   
 The levels of nurse exposures to isoflurane, sevoflurane, and 
desflurane were below the NIOSH REL of 2 ppm.  All of the exposure 
values for isoflurane, sevoflurane, and desflurane obtained by passive 
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sampling were non-detectable.  The levels of exposure for isoflurane 
obtained by active sampling were also non-detectable.  However, 
exposure values for sevoflurane and desflurane obtained by active 
sampling were detectable.  The mean exposure for sevoflurane was 
0.32 ± 0.29 ppm.  The maximum and minimum exposures were 0.98 
and 0.04 ppm.  In determining the descriptive statistics, the censored 
data were adjusted by equation 1.  The 95% CI was from 0.16 to 0.48 
ppm.  The mean exposure for desflurane was 0.34 ± 0.22 ppm.  The 
maximum and minimum exposures were 0.80 and 0.06 ppm.  The 95% 
CI was from 0.18 to 0.50 ppm.    
The ACGIH® Additive Mixture Formula was used to determine if 
the NIOSH REL was exceeded by simultaneous exposure to sevoflurane 
and desflurane.  This formula applies to the additive model.  The 
additive model is when the combined biological effect of the agents of 
the mixture is equal to the sum of each of the agents alone.  The 
formula is: 
               1....
2
21
1
≤++
n
n
T
C
T
C
T
C
                              Equation 2 
If the sum of the equation exceeds one, then the thresold limit of 
the mixture should be considered as being exceeded (ACGIH®, 2005).  
After applying this formula, it should be considered that the NIOSH REL 
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for halogenated anesthetics was not exceeded.  However, it should be 
noted that in one case (Nurse C), the sum approached one (0.8).   
A summary of the statistical data is presented below in Table 8. 
Summary of Waste Anesethetic Gas Exposure Data. 
 
Table 8.  Summary of Waste Anesthetic Gas Exposure Data. 
Mean
Standard 
Deviation
Minimum, 
Maximum
95% 
Confidence 
Interval
Nitrous Oxide 2.12 2.18 0.06, 8.7 0.91, 3.33
Isoflurane 0.08* 0.002* 0.08*, 0.09* 0.08*, 0.09*
Sevoflurane 0.32 0.29 0.04, 0.98 0.16, 0.48
Desflurane 0.34 0.22 0.06, 0.80 0.18, 0.50
n = 15 for each anesthetic agent
* Non-detected values adjusted by equation 1.
parts per million
Anesthetic 
Agents
 
 
 Currently, there are no OSHA PELs for the waste anesthetic 
agents involved in this study.  The NIOSH REL for nitrous oxide is 25 
ppm TWA over the period of administration.  ACGIH® has a TLV® for 
nitrous oxide of 50 ppm.  The NIOSH REL for halogenated anesthetic 
agents is a ceiling limit of 2 ppm.  ACGIH® does not have TLVs® for 
the halogenated anesthetic agents involved in this study.  A summary 
of the occupational exposure limits is presented in Table 9. Summary 
of Occupational Exposure Limits for Waste Anesthetic Gases. 
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Table 9.  Summary of Occupational Exposure Limits for Waste 
Anesthetic Gases (ACGIH, 2005 and NIOSH, 1977). 
Anesthetic 
Agent 
NIOSH 
REL
ACGIH® 
TLV®-TWA
OSHA    
PEL-TWA
Nitrous Oxide 251 50 None
Isoflurane 22 None None
Sevoflurane 22 None None
Desflurane 22 None None
1 - TWA over the period of administration
2 - Ceiling Limit
parts per million
 
 
 
Comparison of Passive and Active Sampling Methods 
 
 In order to compare the passive and active sampling methods, an 
ANOVA was performed.  The ANOVA allowed for a comparison of the 
mean values calculated among the exposure levels of the passive and 
active sampling methods for halogented anesthetics.  All of the 
censored data were applied to the formula in equation 1.  For the 
purposes of this study, the significance level was α = 0.05.  A p-value 
less than 0.05 suggests that there is a statistically significant 
difference among the means, whereas, a p-value greater than 0.05 
suggests there is no statistically significant difference among the 
means.   
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 The results of the ANOVA indicated a statistically significant 
difference (p < 0.05) among the mean values of the analytical data 
from passive and active sampling methods.   
Three variables that may explain the difference among mean 
values related to passive sampling are sampling time, back diffusion 
and variability of anesthetic gas concentrations. 
The sampling time for measuring halogenated anesthetic agents 
using the passive sampling method was three hours.  This sampling 
time yielded detection limits of 0.4 ppm for isoflurane and sevoflurane, 
and 0.6 ppm for desflurane.  The sampling time for measuring 
halogenated anesthetic agents using the active sampling method was 
one hour.  This sampling time yielded detection limits of 0.09 ppm, 
0.08 ppm, and 0.1 ppm for isoflurane, sevoflurane, and desflurane, 
respectively.  The detection limits for the passive sampling method 
were in the same range as the measured concentrations of 
halogenated anesthetic agents in the PACU.  According to the 
laboratory, a sample time of eight hours for the passive sampling 
method would have yielded a detection limit of 0.1 ppm for isoflurane 
and sevoflurane, and 0.2 ppm for desflurane.  These detection limits 
would have been similar to the active sampling method detection 
limits, therefore, allowing a better comparison.  However, a 
disadvantage of the eight hour sample time from a regulatory 
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perspective is the NIOSH ceiling limit REL of 2 ppm.   This ceiling limit 
cannot be exceeded at any time during the workshift.  Therefore, it is 
required to keep the sample time as short as possible to determine 
peak exposure concentrations.       
Once sampling has started, back diffusion may have occurred if 
the vapor pressure of the analyte at the sorbent surface was greater 
than the external concentration.   Theoretically, the patient exhales 
the greatest concentration of anesthetic gases upon arrival to the 
PACU.  As the patient’s length of time in the PACU increases, the 
concentration of gases exhaled will decrease.   
The variability of anesthetic gas concentrations may also explain 
the differences between the means of the exposure levels.  The 
passive sampler may not have the ability to collect the “short-lived” 
analyte in the sorbent material (i.e. coconut charcoal).  However, this 
may not be a problem if the sampling time is in excess of the time 
constant of the passive sampler (Cohen, et al, 2001).  The time 
constant (i.e. the time it takes a molecule to diffuse into the sampler 
under steady-state conditions) for most commercial passive samplers 
is between one and ten seconds (Cohen, et al, 2001).   
There could also be differences in adsorption efficiencies in the 
sorbent materials.  The Anasorb® 747 tubes used during active 
sampling contained a synthetic carbon with a low ash content.  The 
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ChemExpressTM monitors used during passive sampling contained 
coconut charcoal.  According to SKC, Inc., dynamic uptake studies 
demonstrated that Anasorb® sorbent material collected less water 
vapor than the coconut charcoal, thereby increasing desorption 
efficiencies (SKC Inc, 2001).    
  
 
 
PACU Ventilation 
 
 NIOSH recommends the following to reduce exposures to 
anesthetic gases:  monitor air in the personal breathing zone of the 
affected worker; monitor the room air; determine HVAC system 
performance in removing anesthetic gases from the room, if exposures 
are above the RELs increase the amount of make-up air into the room; 
and institute a worker education program.  
The primary engineering control to reduce exposures to 
anesthetic gases within a PACU is the HVAC system.  Hospitals must 
be constructed to the design and construction standards described in 
Chapter 59A-3 of the Florida Administrative Code.  The requirements 
for PACU HVAC systems are a minimum of six room air changes per 
hour with a minimum of 33% fresh air.  The relative pressure within a 
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PACU is required to be neutral to the adjacent areas (International 
Code Council, Inc., 2004).   
 According to hospital engineering personnel, the HVAC system in 
the PACU where the study was performed is maintained regularly.  
They also stated the system is operating at six room air changes per 
hour with 33% fresh air, and the pressure is neutral to the adjacent 
areas. 
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Conclusions 
 
 The exposure levels of nitrous oxide were below the NIOSH 
TWA-REL of 25 ppm.  The exposure levels of nurse to isoflurane, 
sevoflurane, and desflurane were below the NIOSH ceiling limit REL of 
2 ppm.   
There was a difference in the results between active and passive 
sampling methods.  The results of the ANOVA indicated a statistically 
significant difference (p < 0.05) among the mean values of the 
exposure data from active and passive sampling methods.   
Future studies are warranted to further assess nurse exposure to 
waste anesthetic gases.  Investigators measuring exposures to 
halogenated anesthetic agents by passive sampling methodologies 
should pay close attention to the sample time and corresponding 
detection limits.  Future studies should also focus on variables 
associated with exposure to anesthetic gases.  These include:  patient 
load in the PACU; the variability of nitrous oxide compared to 
halogenated gases used in patient anesthesia; the amount of post 
operative care needed; patient body size and minimum alveolar 
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concentration (MAC) of the anesthetic agent administered; examination 
of the procedure of scavenging anesthetic gases exhaled by the patient 
at the end of surgery before transfer to the PACU; and HVAC system 
operation and performance.  Another variable to consider includes the 
density of these agents compared with that of air.  Since these agents 
are heavier than air, a few samples should be obtained close to ground 
level to determine if excessive concentrations of these agents are 
accumulating.   These studies will be helpful to further assess the level 
of exposure of PACU nurses to waste anesthetic gases.      
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